Virbac

Virbac Donates 29,000 Heartworm Doses to Kansas City Shelter

Image
Virbac Donates 29,000 Heartworm Doses to Kansas City Shelter

Westlake, Texas – October 16, 2026 -- Virbac has donated more than 29,000 doses of IVERHART MAX Chews to KC Pet Project, the municipal animal shelter for Kansas City, Missouri, to protect its dogs against heartworm disease and intestinal parasites.

Shelter treats 300 heartworm-positive dogs while screening 8,263 intakes

KC Pet Project cares for more than 16,000 pets each year. It took in 8,263 dogs over the past 12 months, and each receives preventive care at intake. The donation supports that standard of care for every dog entering the shelter.

The shelter is currently treating about 300 dogs diagnosed with heartworm while in its care, according to Dr. Heather Kennedy, chief veterinary officer of KC Pet Project.

Virbac H1 2026 Revenue Rises 7.4%, Confirms Upper-End Guidance

Image
Virbac H1 2026 Revenue Rises 7.4%, Confirms Upper-End Guidance

Paris – September 20, 2026 -- Virbac posted first-half 2026 revenue growth of 7.4% at constant exchange rates and currencies (CERS), lifting its adjusted EBIT margin to 18.8%, up 0.5 percentage points from H1 2025.

Companion animal segment leads growth at 10.0%, farm animal follows at 6.7%

The animal health group's Supercharge platforms, excluding Thyronorm, expanded around 12% at CERS, becoming a key driver of top-line performance. Growth split into a volume/mix effect of approximately 5.4% and a price increase of roughly 2%.

Net income climbs 5.9% to €87.1 million

The margin gain stemmed from a favorable gross margin mix, partially offset by higher operating expenses tied to H1/H2 phasing effects.